banner

News

Sep 17, 2019
Category: General
Posted by: jettebang

Info on Friday morning 

Sep 4, 2019
Category: General
Posted by: jettebang

New deadline for registration and submission of abstract is September 13th at 12 a.m.

Sep 4, 2019
Category: General
Posted by: jettebang

A beautiful morning run

Feb 5, 2019
Category: General
Posted by: jettebang

We are happy to announce that registration for First Scandinavian Baltic Pancreas Symposium, 20-21 September 2019, opens at the end of February on www.OPAC.nu

Oct 18, 2018
Category: General
Posted by: jettebang

The program for First Scandinavia Baltic Pancreas Symposium, September 2019 is now available on our website www.opac.nu


About us

Odense Pancreas Center (OPAC) is a multi-disciplinary research organization focusing on personalized medicine in benign and malignant pancreatic diseases (PD).

OPAC was appointed Center of Clinical Excellence in July 2017 by the Region of Southern Denmark, and OPAC comprises ten departments/institutions working on PD on different levels:

HPB Section, Department of Surgery

Department of Clinical Oncology

Department of Clinical Pathology

Department of Gastroenterology and Hepatology

Department of Endocrinology

Department of Clinical Genetics

Department of Paediatrics (Hans Christian Andersen Childrens Hospital)

Department of Radiology

Department of Nuclear Medicine

Odense Patient Explorative Network (OPEN)

OPAC covers all kinds of PD, and OPAC collaborates with several international consortiums. OPAC activities are closely monitored by an International Advisory Board.

OPAC Infrastructure

 ORG BLÅ

 

                                                              OPAC sekr 


Research plan

Research in benign as well as malignant pancreatic diseases (PD) has changed from using traditional imaging and basic histopathologic techniques towards individual assessment of disease characteristics, based on advanced digital pathological, immune-histochemical and molecular analyses as well as proteomics. These emerging technologies have provided new - however still limited - insights into the morphological, proteomic and genomic landscape of PD. The clinical goals in PD have changed accordingly by aiming at morphologically and genetically identifying the patient that is most likely to benefit from a specific treatment - or redesigning treatment based on proteomic or molecular data to target specific mutations or proteins. The next major steps in PD research and clinical development will involve such individual characterization of disease characteristics, and OPAC aims to be a frontrunner in using and improving this approach.

Therefore, the overall goal of OPAC activities and OPAC research plan is Personalized Medicine in Pancreatic Diseases, and OPAC focuses on two major areas: A) Benign PD and B) Malignant PD.

This approach supports the translational research aspect and will direct the majority of resources into ongoing and planned OPAC trials focusing on personalized medicine in benign and malignant PD.

Overall OPAC research strategy

PERSONALIZED MEDICINE IN PANCREATIC DISEASES

 
WP: Working Packages (see OPAC Trials)

 



OUH